India Approves BPaLM Regimen for Drug-Resistant TB

Sep 6, 2024, 11:51 AM

The Union Health Ministry of India has approved the introduction of a new, shorter, and more efficacious treatment regimen for drug-resistant tuberculosis (TB). The BPaLM regimen, which consists of a four-drug combination—Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin—has been proven to be safe and more effective. This novel treatment will be implemented under the National TB Elimination Program and is expected to benefit India's 75,000 drug-resistant TB patients.